Avaxia Biologics, Inc.
Avaxia is a clinical stage biotech company developing gut targeted antibody therapeutics.
Avaxia is developing gut-targeted antibody therapeutics. Avaxia's products are designed to be safe and effective for oral administration with minimal systemic side effects. Our lead anti-TNF product, AVX-470, is in clinical development for inflammatory bowel disease and is also being developed under a government contract for GI acute radiation syndrome. Pharma partners have expressed interest in AVX-470 and we plan to license after Phase 1b.